
ChromaDex’s TruNiagen sales rise, but legal costs, higher operating expenses drive bigger loss
ChromaDex reported rising sales of its TruNiagen finished product. But increased operating expenses outpaced rising sales resulting in the company reporting even bigger losses than were forecast.